drugset / Trial / NCT03853993

Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (15µg/0.5ml)

NCT03853993

Phase 3 Completed 2380 enrolled Sinovac Biotech Co., Ltd
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to evaluate the safety and immunogenicity of quadrivalent influenza vaccine in healthy subjects aged over 3 years

Timeline

Start
2018-01-23
Primary completion
2018-08-17
Completion
2018-10-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Quadrivalent influenza vaccine Vaccine 15 ug
Comparator Trivalent influenza vaccine (contains B/Victoria strain) Vaccine 15 ug
Comparator Trivalent influenza vaccine (contains B/Yamagata strain) Vaccine 15 ug

Indications